Time for a Paradigm Shift?

How long before the United States reforms its policies regarding skilled technical professional immigration? There is the typical lifetime salary and benefit reduction of $1 million (US) for millions of high skilled American scientists, engineers, and programmers who have been permanently displaced from the fields they trained in by cheap, pliant foreign labor, often from third-world nations, who labor under conditions of quasi-indentured servitude. Their employer-designed work visas are conditi

Written byGene Nelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

How long before the United States reforms its policies regarding skilled technical professional immigration? There is the typical lifetime salary and benefit reduction of $1 million (US) for millions of high skilled American scientists, engineers, and programmers who have been permanently displaced from the fields they trained in by cheap, pliant foreign labor, often from third-world nations, who labor under conditions of quasi-indentured servitude. Their employer-designed work visas are conditioned on the immigrants being continuously employed. Employers and immigration attorneys have praised the "remarkable loyalty" of H-1B visa holders.

The numbers are outrageous. There have been about 17.3 million visa admissions in just five high-skill visa programs between 1985 and 2002.1

A paradigm shift is mandated. While a small number of people derive economic and/or political benefits from the programs that began with the obscure 1976 Eilberg Amendment, these dangerous policies demand immediate reform, before the next 9/11.

Gene Nelson, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies